The result was announced during trading hours today, 29 July 2011.

Meanwhile, the BSE Sensex was down 43.15 points, or 0.24%, to 18,166.37.

On BSE, 5.57 lakh shares were traded in the counter as against an average daily volume of 5.08 lakh shares in the past one quarter.

The stock hit a high of Rs 227.65 and a low of Rs 215.70 so far during the day. The stock had hit a 52-week high of Rs 344.40 on 26 October 2010 and a 52-week low of Rs 179.60 on 29 July 2010.

The stock had underperformed the market over the past one month until 28 July 2011, falling 15.96% compared with the Sensex's 1.53% fall. The scrip had also underperformed the market in past one quarter, sliding 28.61% as against 5.61% decline in the Sensex.

The mid-cap drug maker has an equity capital of Rs 70.44 crore. Face value per share is Rs 10.

Orchid Chemicals' earnings before interest, taxation, depreciation and amortization (EBITDA) rose 7.89% to Rs Rs 88.94 crore in Q1 June 2011 over Q1 June 2010.

Orchid Chemicals & Pharmaceuticals' Chairman and Managing Director K Raghavendra Rao said, "Our performance continues on a strong trajectory and we are confident of scaling further heights in the quarters to come. We have entered into long-term contractual agreements with large multinational companies (MNCs) including Hospira for supply of our niche active pharmaceutical ingredients (APIs) and formulations, which have augured well. Given the less-competitive landscape for most of our products, we are confident of a strong growth going forward."

In the API space, Orchid's cumulative filings of its US drug master files (DMFs) stood at 83. The break-up of the total filings is 27 in the Cephalosporin space, 43 in NPNC space, 2 in the Betalactam segment and 11 in the Carbapenems segment. The cumulative filings of Certificate of Suitability for the European market stood at 21, which include 14 in Cephalosporin space, 6 in non-Cephalosporin (NPNC) and 1 in the Betalactam segment.

Orchid's cumulative Abbreviated New Drug Application (ANDA) filings for the US market stands at 43. This includes 8 Para IV First-to-File filings. Out of this, the company has already settled with the Innovator for 4 products. The break-up of the total ANDAs are 13 in Cephalosporin space and 30 NPNC space.

In the European Union (EU) region, the cumulative count of Marketing Authorisations (MAs) files stood at 25. The break-up of the total MA filings is 13 in Cephalosporin space and 12 in the NPNC space.

The final approved ANDAs count stood at 21 at the end of Q1 June 2011. The break-up of the total final ANDA approval count comprises of 11 in Cephalosporin space and 10 in NPNC space.

In the EU region, the cumulative count of MA approved stood at 21. The break-up of the total MA aproval count is 9 in the the Cephalosporin space and 12 in the Oral NPNC space.